CINECA IRIS Institutional Research Information System

VIVALDI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.109
EU - Europa 2.022
AS - Asia 1.257
AF - Africa 309
SA - Sud America 15
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.038
IT - Italia 727
CN - Cina 616
SE - Svezia 515
SG - Singapore 413
CI - Costa d'Avorio 221
BG - Bulgaria 178
DE - Germania 155
GB - Regno Unito 155
AT - Austria 81
CA - Canada 69
VN - Vietnam 62
TR - Turchia 60
SN - Senegal 56
FI - Finlandia 55
RU - Federazione Russa 53
IN - India 35
HK - Hong Kong 30
NG - Nigeria 28
FR - Francia 26
BR - Brasile 12
KR - Corea 12
PL - Polonia 12
UA - Ucraina 12
AU - Australia 9
NL - Olanda 9
JP - Giappone 8
BE - Belgio 6
IR - Iran 6
RO - Romania 6
CH - Svizzera 5
ES - Italia 5
LT - Lituania 5
TW - Taiwan 4
CZ - Repubblica Ceca 3
EE - Estonia 3
ID - Indonesia 3
NZ - Nuova Zelanda 3
AE - Emirati Arabi Uniti 2
HU - Ungheria 2
IE - Irlanda 2
MX - Messico 2
TN - Tunisia 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
EU - Europa 1
HR - Croazia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MY - Malesia 1
NP - Nepal 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 8.725
Salva come PNG Salva come JPEG
Città #
Santa Clara 602
Woodbridge 520
Fairfield 450
Chandler 448
Houston 349
Ann Arbor 336
Shanghai 279
Ashburn 274
Abidjan 221
Singapore 189
Wilmington 180
New York 178
Seattle 178
Sofia 177
Cambridge 165
Boardman 143
Princeton 117
Lawrence 103
Milan 103
Florence 96
Beijing 89
Pisa 80
Vienna 78
London 74
Medford 71
Ottawa 57
Dakar 56
Istanbul 54
Serra 49
San Diego 47
Des Moines 33
Frankfurt am Main 33
Fuzhou 30
Hong Kong 28
Lagos 28
Bremen 27
Lancaster 27
Ogden 27
Dearborn 26
Kent 26
Nanjing 25
Los Angeles 24
Cascina 19
Helsinki 19
Council Bluffs 18
Düsseldorf 18
Hyderabad 17
Rome 17
Dong Ket 16
Hebei 16
Quanzhou 16
Norwalk 14
Seacroft 14
Vicopisano 12
Warsaw 11
Boulder 10
Changsha 10
Redwood City 10
Genoa 9
Bologna 8
Jacksonville 8
Lappeenranta 8
Lucca 8
Nanchang 8
Shenyang 8
Toronto 8
Pietrasanta 7
Center 6
Hefei 6
Iowa City 6
Redmond 6
Wuhan 6
Brussels 5
Castiglione Chiavarese 5
Columbus 5
Piombino 5
Pune 5
Shenzhen 5
Turin 5
Washington 5
Bedizzole 4
Chengdu 4
Guangzhou 4
Izmir 4
Jiaxing 4
Modugno 4
Nürnberg 4
Phoenix 4
Pistoia 4
Positano 4
Stockholm 4
Zurich 4
Detroit 3
Fort Worth 3
Grafing 3
Hangzhou 3
Manchester 3
Massa 3
Munich 3
San Giuliano Terme 3
Totale 6.548
Salva come PNG Salva come JPEG
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 249
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 160
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 138
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 138
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 137
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 135
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 135
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 125
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 123
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients 122
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 122
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. 120
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 117
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 117
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 114
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 114
Prognostic value of CD133 caused by mutant K-Ras and B-Raf 113
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 111
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 109
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 107
Prognostic value of CD133 caused by mutant K-RAS and B-RAF letter. 104
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. 104
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. 103
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 102
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 102
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 102
Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients 101
Not only chemotherapy in the second-line treatment of metastatic gastric cancer. 98
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 98
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? 96
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 96
Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection 95
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 94
Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence. 94
Tumor regression grade (TRG) evaluation of 29 borderline/locally advanced pancreatic cancers (LAPCs) after neoadjuvant chemotherapy (NACT) using different pathological scores: a clinical and prognostic correlation 93
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 92
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 89
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. 88
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 88
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 87
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. 86
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration 86
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 84
Neuroendocrine Liver Metastases 83
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 82
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 81
Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation 81
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 80
Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis 80
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology 80
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions 79
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer 78
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: Is hepatic arterial infusion chemotherapy the best option? 75
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer 74
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications 74
Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study 73
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 72
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 72
Cholangiocarcinoma: new perspectives for new horizons 71
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 70
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer 66
About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial” 65
null 61
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 59
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma 58
null 58
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 58
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 58
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer 57
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 56
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 55
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 55
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study 54
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial 52
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 51
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 50
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 50
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 49
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 49
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients 49
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 48
null 48
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 48
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 48
In Reply 48
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 46
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 45
Bone metastases in biliary cancers: A multicenter retrospective survey 45
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 45
Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients 43
null 42
Assessment of radiation sensitivity of unresectable intrahepatic cholangiocarcinoma in a series of patients submitted to radioembolization with yttrium-90 resin microspheres 42
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 42
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer 41
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 40
Equivalent efficacy but different safety profiles of gemcitabine plus nab-paclitaxel and folfirinox in metastatic pancreatic cancer 40
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 40
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 39
Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study) 38
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 38
Totale 8.069
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020453 0 0 0 0 0 0 110 90 92 63 73 25
2020/2021523 20 41 20 21 26 106 19 39 55 62 30 84
2021/20221.030 14 20 17 27 171 217 30 35 67 81 90 261
2022/20231.863 186 280 154 93 177 206 15 128 450 7 141 26
2023/20241.209 73 96 144 54 161 171 154 47 37 41 90 141
2024/20251.821 28 199 90 236 443 679 146 0 0 0 0 0
Totale 9.049